{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:24:58Z","timestamp":1793917498195,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuropharm.2026.111155","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:57:05Z","timestamp":1787155025000},"page":"111155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The \u03b2-carboline derivative Carbacetam attenuates mortality and neuroendocrine dysfunction in a rodent model of traumatic brain injury: A multi-target pharmacological and molecular docking study"],"prefix":"10.1016","volume":"300","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4166-6397","authenticated-orcid":false,"given":"Danylo I.","family":"Yevstifeiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-3728","authenticated-orcid":false,"given":"Sergiy V.","family":"Ziablitsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0766-7141","authenticated-orcid":false,"given":"Nadia O.","family":"Aleksandrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-3720","authenticated-orcid":false,"given":"Serhii L.","family":"Bohza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7839-7590","authenticated-orcid":false,"given":"Mykyta Yu","family":"Bilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4095-1427","authenticated-orcid":false,"given":"Veronika A.","family":"Mamoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7518-4088","authenticated-orcid":false,"given":"Sofiia V.","family":"Moisieienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7974-9128","authenticated-orcid":false,"given":"Aryna O.","family":"Shevchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0843-8195","authenticated-orcid":false,"given":"Mykola S.","family":"Babenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111155_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2015.03.004","article-title":"DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications","volume":"151","author":"Abbassi","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2026.111155_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01053142","article-title":"Multiple mechanisms underlying nootropic drug-induced enhancement of neuronal responses mediated by activation of glutamate NMDA-type receptors","volume":"25","author":"Abramets","year":"1993","journal-title":"Neurophysiology"},{"key":"10.1016\/j.neuropharm.2026.111155_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10143-024-03088-3","article-title":"Acute and chronic hypopituitarism following traumatic brain injury: a systematic review and meta-analysis","volume":"47","author":"Aljboor","year":"2024","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.neuropharm.2026.111155_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2025.102015","article-title":"Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: a scoping review","volume":"39","author":"Batson","year":"2025","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib5","doi-asserted-by":"crossref","first-page":"12690","DOI":"10.1523\/JNEUROSCI.2808-10.2010","article-title":"Loss of quinone reductase 2 function selectively facilitates learning behaviors","volume":"30","author":"Benoit","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111155_bib6","doi-asserted-by":"crossref","first-page":"11417","DOI":"10.1021\/bi049162o","article-title":"Crystal structure of quinone reductase 2 in complex with resveratrol","volume":"43","author":"Buryanovskyy","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2026.111155_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/BJ20071373","article-title":"Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2","volume":"413","author":"Calamini","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2026.111155_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2026.111155_bib9","article-title":"Quinone reductase 2 reads H3 serotonylation to support neuronal maturation","author":"Chen","year":"2026","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70166","article-title":"Carboline hybrids as potential multitarget-directed Anti-Alzheimer\u2019s disease agents: a comprehensive analysis of design strategies and structure-activity relationships","volume":"358","author":"Dash","year":"2025","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.neuropharm.2026.111155_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.neuropharm.2026.111155_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00506671","article-title":"Synthesis of condensed derivatives of indolo[2,3-c]pyrylium salts and \u03b2-carbolines","volume":"21","author":"Dulenko","year":"1985","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.neuropharm.2026.111155_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0006-8993(81)90067-6","article-title":"Responses to cortical injury: I. Methodology and local effects of contusions in the rat","volume":"211","author":"Feeney","year":"1981","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2026.111155_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019264","article-title":"\u03b2-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites","volume":"6","author":"Frost","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.111155_bib15","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.cell.2023.10.007","article-title":"Structural basis for human Cav1.2 inhibition by multiple drugs and the neurotoxin calciseptine","volume":"186","author":"Gao","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2026.111155_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0376-8716(99)00148-9","article-title":"Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors","volume":"60","author":"Glennon","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2026.111155_bib18","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0067-20.2020","article-title":"Muscarinic-dependent miR-182 and QR2 expression regulation in the anterior insula enables novel taste learning","volume":"7","author":"Gould","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2026.111155_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162120","article-title":"Specific quinone reductase 2 inhibitors reduce metabolic burden and reverse Alzheimer's disease phenotype in mice","volume":"133","author":"Gould","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2026.111155_bib17","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1523\/JNEUROSCI.1243-20.2020","article-title":"Dopamine-dependent QR2 pathway activation in CA1 interneurons enhances novel memory formation","volume":"40","author":"Gould","year":"2020","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111155_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075049","article-title":"Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"13","author":"Guan","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2026.111155_bib21","article-title":"A novel targeted nanoparticle for traumatic brain injury treatment: combined effect of ROS depletion and calcium overload inhibition","volume":"11","author":"Han","year":"2022","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.neuropharm.2026.111155_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.fct.2009.12.019","article-title":"beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)","volume":"48","author":"Herraiz","year":"2010","journal-title":"Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.neuropharm.2026.111155_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505962","article-title":"Nanocatalytic neuroprotection and neurological recovery post\u2010traumatic brain injury","volume":"12","author":"Hong","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.neuropharm.2026.111155_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5234","article-title":"Evolutionary analysis of quinone reductases 1 and 2 suggests that NQO2 evolved to function as a pseudoenzyme","volume":"33","author":"Islam","year":"2024","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.neuropharm.2026.111155_bib25","article-title":"Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease","volume":"21","author":"Kac","year":"2025","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"10.1016\/j.neuropharm.2026.111155_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/hmg\/ddl437","article-title":"The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease","volume":"16","author":"Kimura","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2026.111155_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.31688\/ABMU.2019.54.1.17","article-title":"Carbacetam effect on behavioral reactions in experimental Alzheimer's disease","volume":"54","author":"Kmet","year":"2019","journal-title":"Arch. Balkan Med. Union"},{"key":"10.1016\/j.neuropharm.2026.111155_bib28","unstructured":"Komissarov, I.V., Leshchinskaya, E.Y., Psychopharmacotherapeutic potential of tetramethyleneharmanes. Zh. Akad. Med. Nauk Ukrainy 4 (1998), 199\u2013215 [in Ukrainian]."},{"key":"10.1016\/j.neuropharm.2026.111155_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1440-1681.2000.03194.x","article-title":"Inhibitory action of ambocarb on voltage-operated sodium channels in rat isolated hippocampal pyramidal neurons","volume":"27","author":"Kopanitsa","year":"2000","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib30","unstructured":"Kut'ko, I.I., Sitchenko, N.M., Clinical efficacy of the Ukrainian preparation ambocarb. Lik. Sprava (9\u201312), (1995), 96\u201398 [in Ukrainian]."},{"key":"10.1016\/j.neuropharm.2026.111155_bib31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-018-0833-4","article-title":"Cryo-EM structure of the human \u03b11\u03b23\u03b32 GABAA receptor in a lipid bilayer","volume":"565","author":"Laverty","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111155_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.2005.02250.x","article-title":"Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury","volume":"62","author":"Leal-Cerro","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib33","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing actions of neurosteroids on GABAA receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2026.111155_bib34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/fcp.12656","article-title":"Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection?","volume":"35","author":"Lerouet","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1474-4422(08)70164-9","article-title":"Moderate and severe traumatic brain injury in adults","volume":"7","author":"Maas","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13321-021-00522-2","article-title":"Gnina 1.0: molecular docking with deep learning","volume":"13","author":"McNutt","year":"2021","journal-title":"J. Cheminf."},{"key":"10.1016\/j.neuropharm.2026.111155_bib37","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JAD-240078","article-title":"Leucettinib-21, a DYRK1A kinase inhibitor as clinical drug candidate for alzheimer's disease and Down syndrome","volume":"101","author":"Meijer","year":"2024","journal-title":"J. Alzheimers Dis. JAD"},{"key":"10.1016\/j.neuropharm.2026.111155_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2026.111155_bib39","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/S0140-6736(15)00386-4","article-title":"Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial","volume":"386","author":"Nichol","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2026.111155_bib40","doi-asserted-by":"crossref","first-page":"31311","DOI":"10.1074\/jbc.M005141200","article-title":"Identification of the melatonin-binding site MT3 as the quinone reductase 2","volume":"275","author":"Nosjean","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2026.111155_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2026.111155_bib42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early parkinson disease: a randomized trial","volume":"172","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuropharm.2026.111155_bib43","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/pro.647","article-title":"X-ray structural studies of quinone reductase 2 nanomolar range inhibitors","volume":"20","author":"Pegan","year":"2011","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.neuropharm.2026.111155_bib44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/neu.2008.0586","article-title":"Workshop scientific team and advisory panel members, classification of traumatic brain injury for targeted therapies","volume":"25","author":"Saatman","year":"2008","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.neuropharm.2026.111155_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10593-013-1229-x","article-title":"A drug mystery of heterocycles: various molecules for one target or one compound for multiple targets?","volume":"49","author":"Shcherbakova","year":"2013","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.neuropharm.2026.111155_bib46","article-title":"The emerging role of neurosteroids: novel drugs brexanalone, sepranolone, zuranolone, and ganaxolone in mood and neurological disorders","volume":"16","author":"Singhal","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.neuropharm.2026.111155_bib47","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1411090","article-title":"A clinical trial of progesterone for severe traumatic brain injury","volume":"371","author":"Skolnick","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2026.111155_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242174","article-title":"Dihydronicotinamide riboside promotes cell-specific cytotoxicity by tipping the balance between metabolic regulation and oxidative stress","volume":"15","author":"Sonavane","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.111155_bib49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3109\/02699052.2015.1065344","article-title":"Embracing failure: what the phase III progesterone studies can teach about TBI clinical trials","volume":"29","author":"Stein","year":"2015","journal-title":"Brain Inj."},{"key":"10.1016\/j.neuropharm.2026.111155_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1109406","article-title":"Are GABAergic drugs beneficial in providing neuroprotection after traumatic brain injuries? A comprehensive literature review of preclinical studies","volume":"14","author":"Sudhakar","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105383","article-title":"The molecular determinants of neurosteroid binding in the GABA(A) receptor","volume":"192","author":"Sugasawa","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-023-06556-w","article-title":"Cryo-EM structures reveal native GABAA receptor assemblies and pharmacology","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111155_bib53","article-title":"Identification of harmine and \u03b2-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies","volume":"162","author":"Tarpley","year":"2021","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2026.111155_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0091-3057(94)90174-0","article-title":"Influence of flumazenil on the learning-enhancing effect of ambocarb in rats","volume":"47","author":"Titievsky","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2026.111155_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/dneu.20778","article-title":"Toward a comprehensive neurobiology of IGF-I","volume":"70","author":"Torres-Aleman","year":"2010","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2026.111155_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-023-02709-3","article-title":"The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP-intoxicated mice","volume":"131","author":"Vallucci","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2026.111155_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.09.019","article-title":"NRH:quinone reductase 2: an enzyme of surprises and mysteries","volume":"71","author":"Vella","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111155_bib59","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1089\/neu.2018.6162","article-title":"Diazepam inhibits post-traumatic neurogenesis and blocks aberrant dendritic development","volume":"36","author":"Villasana","year":"2019","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.neuropharm.2026.111155_bib60","article-title":"Brexanolone, zuranolone and related neurosteroid GABAA receptor positive allosteric modulators for postnatal depression","volume":"2025","author":"Wilson","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2026.111155_bib61","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa1404304","article-title":"Very early administration of progesterone for acute traumatic brain injury","volume":"371","author":"Wright","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2026.111155_bib62","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2012.13256","article-title":"Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: citicoline Brain Injury Treatment Trial (COBRIT)","volume":"308","author":"Zafonte","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2026.111155_bib64","series-title":"Analysis of the Neurologic Deficit Under the Traumatic Brain Injury and Methods of Its Correction","author":"Ziablitsev","year":"2017"},{"key":"10.1016\/j.neuropharm.2026.111155_bib63","series-title":"Syndromes of traumatic disease in traumatic brain injury","author":"Ziablitsev","year":"2020"},{"key":"10.1016\/j.neuropharm.2026.111155_bib65","first-page":"11","article-title":"Experimental investigation on carbacetam influence on hypothalamus tissue in brain injury","volume":"14","author":"Ziablytsev","year":"2018","journal-title":"Med. Sci. Ukr."},{"key":"10.1016\/j.neuropharm.2026.111155_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiol. Stress"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:06Z","timestamp":1793915286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":66,"alternative-id":["S0028390826003308"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111155","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b2-carboline derivative Carbacetam attenuates mortality and neuroendocrine dysfunction in a rodent model of traumatic brain injury: A multi-target pharmacological and molecular docking study","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111155"}}